Zheng Quan Ri Bao Zhi Sheng·2025-12-01 10:13Core Viewpoint - Yiling Pharmaceutical has launched its self-developed innovative traditional Chinese medicine, Qifang Nasal Tablets, for the treatment of persistent allergic rhinitis, providing a new treatment option for millions of patients in China [1][6]. Group 1: Product Information - Qifang Nasal Tablets are classified as a national Class 1.1 innovative traditional Chinese medicine and have received national invention patents and support from provincial and ministerial key research projects [3]. - The product is based on the clinical experience of Professor Li Shuliang from the Chinese Academy of Medical Sciences and incorporates elements from classic formulas "Yupingfeng San" and "Xinyi San" [6]. - Clinical trials showed a total effective rate of 89% after four weeks of treatment, with significant improvements in nasal and eye symptoms compared to the control group [6]. Group 2: Market Context - Allergic rhinitis is a common chronic disease in China, with a self-reported prevalence rate of 17.6%, indicating that approximately 1 in 6 people suffers from this condition [1]. - The demand for safe, effective, and long-term treatment options is urgent among patients suffering from allergic rhinitis [1]. Group 3: Collaboration and Distribution - Yiling Pharmaceutical has partnered with Alibaba Health to leverage its digital service capabilities for the comprehensive market launch of Qifang Nasal Tablets [6][7]. - Alibaba Health aims to enhance disease knowledge dissemination and improve drug accessibility through its nationwide distribution network [7].